PL1660449T3 - Pochodne aminopropanolu - Google Patents

Pochodne aminopropanolu

Info

Publication number: PL1660449T3
Authority: PL; Poland
Prior art keywords: aminopropanol derivatives; aminopropanol; derivatives; compounds; processes
Prior art date: 2003-08-28

Application number

PL04764563T

Other languages

English (en)

Inventor

Rainer Albert

Eric Francotte

Frédéric Zecri

Markus Zollinger

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-08-28

Filing date

2004-08-27

Publication date

2010-05-31

2003-08-28 Priority claimed from GB0320196A external-priority patent/GB0320196D0/en

2003-10-15 Priority claimed from GB0324206A external-priority patent/GB0324206D0/en

2004-08-27 Application filed by Novartis Ag filed Critical Novartis Ag

2010-05-31 Publication of PL1660449T3 publication Critical patent/PL1660449T3/pl

Links

MXZROAOUCUVNHX-UHFFFAOYSA-N 2-Aminopropanol Chemical class CCC(N)O MXZROAOUCUVNHX-UHFFFAOYSA-N 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
- C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D263/14—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with radicals substituted by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/094—Esters of phosphoric acids with arylalkanols
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
- C07F9/653—Five-membered rings
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/16—Phosphorus containing
- Y10T436/163333—Organic [e.g., chemical warfare agents, insecticides, etc.]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Diabetes (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Virology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Hematology (AREA)
Neurology (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Neurosurgery (AREA)
Otolaryngology (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Vascular Medicine (AREA)
Obesity (AREA)
Emergency Medicine (AREA)

PL04764563T 2003-08-28 2004-08-27 Pochodne aminopropanolu PL1660449T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GB0320196A GB0320196D0 (en)	2003-08-28	2003-08-28	Organic compounds
GB0324206A GB0324206D0 (en)	2003-10-15	2003-10-15	Organic compounds
PCT/EP2004/009589 WO2005021503A1 (en)	2003-08-28	2004-08-27	Aminopropanol derivatives
EP04764563A EP1660449B1 (en)	2003-08-28	2004-08-27	Aminopropanol derivatives

Publications (1)

Publication Number	Publication Date
PL1660449T3 true PL1660449T3 (pl)	2010-05-31

Family

ID=34276809

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL04764563T PL1660449T3 (pl)	2003-08-28	2004-08-27	Pochodne aminopropanolu

Country Status (14)

Country	Link
US (4)	US7528120B2 (pl)
EP (1)	EP1660449B1 (pl)
JP (1)	JP5001653B2 (pl)
CN (3)	CN1874996B (pl)
AT (1)	ATE449069T1 (pl)
AU (1)	AU2004268052B2 (pl)
BR (1)	BRPI0413151A (pl)
CA (1)	CA2535704C (pl)
DE (1)	DE602004024213D1 (pl)
ES (1)	ES2335410T3 (pl)
MX (1)	MXPA06002349A (pl)
PL (1)	PL1660449T3 (pl)
PT (1)	PT1660449E (pl)
WO (1)	WO2005021503A1 (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7781617B2 (en)	2004-07-16	2010-08-24	Kyorin Pharmaceutical Co., Ltd	Effective use method of medicaments and method of preventing expression of side effect
EP1806338B1 (en)	2004-10-12	2016-01-20	Kyorin Pharmaceutical Co., Ltd.	Process for producing 2-amino-2-[2-[4-(3-benzyloxy-phenylthio)-2-chlorophenyl[ethyl]-1,3-propanediol hydrochloride and hydrates thereof. and intermediates the production thereof
ES2529724T3 (es) *	2005-09-09	2015-02-25	Novartis Ag	Tratamiento de enfermedades autoinmunes
PL1932522T3 (pl) *	2005-10-07	2012-09-28	Kyorin Seiyaku Kk	Środek terapeutyczny do leczenia choroby wątroby zawierający jako składnik czynny pochodną 2-amino-1,3-propanodiolu
TWI389683B (zh) *	2006-02-06	2013-03-21	Kyorin Seiyaku Kk	A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
CA2659598A1 (en)	2006-08-08	2008-02-14	Kyorin Pharmaceutical Co., Ltd.	Amino phosphate derivative and s1p receptor modulator having same as an active ingredient
JP5140593B2 (ja)	2006-08-08	2013-02-06	杏林製薬株式会社	アミノアルコール誘導体及びそれらを有効成分とする免疫抑制剤
EP3733161A1 (en)	2007-10-12	2020-11-04	Novartis AG	Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators
TW200946105A (en)	2008-02-07	2009-11-16	Kyorin Seiyaku Kk	Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient
US8580841B2 (en)	2008-07-23	2013-11-12	Arena Pharmaceuticals, Inc.	Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
HRP20160890T1 (hr)	2008-08-27	2016-09-23	Arena Pharmaceuticals, Inc.	Derivati supstituirane tricikličke kiseline kao agonisti s1p1-receptora korisni u liječenju autoimunih i upalnih poremećaja
EP2509938A1 (en) *	2009-12-10	2012-10-17	Novartis AG	Fty720 halogenated derivatives
JP5856980B2 (ja)	2010-01-27	2016-02-10	アリーナファーマシューティカルズ，インコーポレイテッド	（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸およびその塩の調製のためのプロセス
CN105503882B (zh)	2010-03-03	2019-07-05	艾尼纳制药公司	制备s1p1受体调节剂及其晶体形式的方法
BR112012028248A2 (pt)	2010-05-06	2016-08-02	Novartis Ag	derivados de sulfeto de diarila, seu uso, e kit
KR20130066630A (ko)	2010-05-06	2013-06-20	노파르티스 아게	자가면역 질환의 치료
WO2012105574A1 (ja) *	2011-01-31	2012-08-09	国立大学法人長崎大学	光学活性化合物又はその塩の製造方法
PL3242666T3 (pl)	2015-01-06	2025-02-17	Arena Pharmaceuticals, Inc.	Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
BR112017027656B1 (pt)	2015-06-22	2023-12-05	Arena Pharmaceuticals, Inc.	Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo
MX2019009843A (es)	2017-02-16	2020-01-30	Arena Pharm Inc	Compuestos y metodos para el tratamiento de la enfermedad inflamatoria intestinal con manifestaciones extraintestinales.
MX2019009841A (es)	2017-02-16	2020-01-30	Arena Pharm Inc	Compuestos y metodos para el tratamiento de la colangitis biliar primaria.
GB201715786D0 (en) *	2017-09-29	2017-11-15	Univ College Cardiff Consultants Ltd	Compounds
CA3102136A1 (en)	2018-06-06	2019-12-12	Arena Pharmaceuticals, Inc.	Methods of treating conditions related to the s1p1 receptor
CN112955431A (zh)	2018-09-06	2021-06-11	艾尼纳制药公司	可用于治疗自身免疫性病症和炎性病症的化合物
CN111537635B (zh) *	2020-05-11	2021-04-06	成都市科隆化学品有限公司	精确配制醋酸标准曲线溶液及保护氨基酸醋酸检测方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1315735A4 (en) *	2000-08-31	2005-04-06	Merck & Co Inc	Phosphate derivatives as immunoregulatory compounds
CA2442178A1 (en) *	2001-03-26	2002-10-03	Novartis Ag	2-amino-propanol derivatives
CN100516024C (zh)	2002-09-13	2009-07-22	诺瓦提斯公司	氨基-丙醇衍生物
BR0317885A (pt) *	2002-12-30	2005-12-06	Celgene Corp	Composto, isÈmeros s e r enantiomericamente puros do mesmo, composição farmacêutica e métodos de inibir pde4 e mmp, de modular a produção de tnf-alfa, de tratar ou prevenir mds, de tratar doença mieloproliferativa, angiogênese indesejada, câncer, uma doença, inflamação dos pulmões, depressão, distúrbio pulmonar obstrutivo crÈnico, doença inflamatória do intestino, dermatite atópica, psorìase, doença de crohn, artrite reumatóide, asma, eslcerose múltipla e doença cardìaca em um mamìfero e de tratar, prevenir ou controlar a sìndrome de dor regional complexa
CN1777575B (zh) *	2003-04-30	2010-05-12	诺瓦提斯公司	作为1-磷酸-鞘氨醇受体调节剂的氨基-丙醇衍生物
US7129260B2 (en) *	2003-06-02	2006-10-31	Abbott Laboratories	Isoindolinone kinase inhibitors

2004
- 2004-08-27 AT AT04764563T patent/ATE449069T1/de active
- 2004-08-27 ES ES04764563T patent/ES2335410T3/es not_active Expired - Lifetime
- 2004-08-27 WO PCT/EP2004/009589 patent/WO2005021503A1/en not_active Ceased
- 2004-08-27 MX MXPA06002349A patent/MXPA06002349A/es active IP Right Grant
- 2004-08-27 US US10/569,696 patent/US7528120B2/en not_active Expired - Fee Related
- 2004-08-27 CN CN2004800262367A patent/CN1874996B/zh not_active Expired - Fee Related
- 2004-08-27 CN CN2011100601438A patent/CN102175786B/zh not_active Expired - Fee Related
- 2004-08-27 PT PT04764563T patent/PT1660449E/pt unknown
- 2004-08-27 AU AU2004268052A patent/AU2004268052B2/en not_active Ceased
- 2004-08-27 PL PL04764563T patent/PL1660449T3/pl unknown
- 2004-08-27 EP EP04764563A patent/EP1660449B1/en not_active Expired - Lifetime
- 2004-08-27 CA CA2535704A patent/CA2535704C/en not_active Expired - Fee Related
- 2004-08-27 DE DE602004024213T patent/DE602004024213D1/de not_active Expired - Lifetime
- 2004-08-27 JP JP2006524339A patent/JP5001653B2/ja not_active Expired - Fee Related
- 2004-08-27 CN CN2013100825423A patent/CN103193822A/zh active Pending
- 2004-08-27 BR BRPI0413151-7A patent/BRPI0413151A/pt not_active IP Right Cessation
2009
- 2009-02-24 US US12/391,298 patent/US7902175B2/en not_active Expired - Fee Related
2011
- 2011-01-28 US US13/015,825 patent/US20110118210A1/en not_active Abandoned
2012
- 2012-07-11 US US13/546,490 patent/US20120277194A1/en not_active Abandoned

Also Published As

Publication number	Publication date
BRPI0413151A (pt)	2006-10-03
AU2004268052B2 (en)	2009-11-19
MXPA06002349A (es)	2006-05-22
US7902175B2 (en)	2011-03-08
CN102175786B (zh)	2013-07-17
PT1660449E (pt)	2010-01-21
ES2335410T8 (es)	2011-07-01
ATE449069T1 (de)	2009-12-15
CN102175786A (zh)	2011-09-07
US20060264403A1 (en)	2006-11-23
CN1874996B (zh)	2011-05-18
US7528120B2 (en)	2009-05-05
ES2335410T3 (es)	2010-03-26
CA2535704A1 (en)	2005-03-10
CA2535704C (en)	2012-12-11
US20110118210A1 (en)	2011-05-19
WO2005021503A1 (en)	2005-03-10
EP1660449A1 (en)	2006-05-31
US20120277194A1 (en)	2012-11-01
US20090156556A1 (en)	2009-06-18
EP1660449B1 (en)	2009-11-18
CN103193822A (zh)	2013-07-10
JP5001653B2 (ja)	2012-08-15
DE602004024213D1 (en)	2009-12-31
JP2007504111A (ja)	2007-03-01
AU2004268052A1 (en)	2005-03-10
CN1874996A (zh)	2006-12-06

Publication	Publication Date	Title
PL1660449T3 (pl)	2010-05-31	Pochodne aminopropanolu
TW200801003A (en)	2008-01-01	Novel compounds
TW200621729A (en)	2006-07-01	Pyrimidine derivatives
TW200611904A (en)	2006-04-16	Aza-bicyclononanes
TNSN05007A1 (en)	2007-05-14	Novel thiophenylglycoside derivatives, methods for production thereof, medicaments comprising said compounds and use thereof.
MX2009004707A (es)	2009-05-15	Piridina carboxamides como inhibidores 11-beta-hsd1.
MXPA05011596A (es)	2006-01-23	Derivados de amino-propanol como modulador de receptor de esfingosina-1-fosfato.
TW200617009A (en)	2006-06-01	Organic compounds
MX2007005933A (es)	2007-06-20	Compuestos de acetamida como fungicidas.
TNSN07074A1 (en)	2008-06-02	Pyrimidine derivatives
DE602004021472D1 (en)	2009-07-23	Pyrimiidinverbindungen
TW200732323A (en)	2007-09-01	Organic compounds
MXPA06000921A (es)	2006-03-30	Derivados de benzamidazoles como inhibidores de mek.
SE0401762D0 (sv)	2004-07-05	Novel compounds
TW200508197A (en)	2005-03-01	Indolone-acetamide derivatives, processes for preparing them and their uses
TW200500339A (en)	2005-01-01	Pyrrolidine derivatives, and process for the preparation
ZA200604410B (en)	2008-09-25	Imidazole derivatives, processes for preparing them and their uses
TW200738659A (en)	2007-10-16	Novel compounds
JO2734B1 (en)	2013-09-15	Organic compounds
PL1753712T3 (pl)	2009-10-30	Pochodne aminopropanolu
TW200638930A (en)	2006-11-16	Acetylene derivatives
TW200635917A (en)	2006-10-16	Novel compounds
PT1877367E (pt)	2010-01-07	Derivados do acetileno
PL1904482T3 (pl)	2011-06-30	Pochodne indolilomaleimidowe
TW200635916A (en)	2006-10-16	Compounds